Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib in children and adolescents with hereditary medullary thyroid cancer
2011-004934-32Phase 2
- Sponsor
- National Cancer Institute
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of vandetanib in Medullary Thyroid Cancer (MTC) and familial medullary thyroid cancer (FMTC), sponsored by National Cancer Institute. Primary endpoint: Change in tumour size compared to baseline using RECIST.
02
Drugs
vandetanib
03
Conditions
Medullary Thyroid Cancer (MTC)familial medullary thyroid cancer (FMTC)
Beyond the preview
Go deeper on 2011-004934-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004934-32.